Document is current
Any future updates will be listed below
-
Authors
Maeda, Yuichi http://orcid.org/0000-0002-6831-8205
Hirano, Toru http://orcid.org/0000-0001-8467-3154
Ebina, Kosuke http://orcid.org/0000-0002-2426-1024
Hara, Ryota http://orcid.org/0000-0001-8000-3196
Hashimoto, Motomu http://orcid.org/0000-0002-9241-060X
Yamamoto, Wataru http://orcid.org/0000-0002-0810-4221
Murakami, Kosaku
Kotani, Takuya
Hata, Kenichiro
Son, Yonsu http://orcid.org/0000-0001-7244-7715
Amuro, Hideki http://orcid.org/0000-0002-7299-2884
Onishi, Akira http://orcid.org/0000-0002-3120-1273
Jinno, Sadao http://orcid.org/0000-0003-3021-183X
Katayama, Masaki http://orcid.org/0000-0002-0773-7238
Kumanogoh, Atsushi http://orcid.org/0000-0003-4749-7117
-
Funding
Funding for this research was provided by:
Abbie G.K.
Asahi Kasei Pharma Corporation
AYUMI Pharmaceutical companies
Chugai Pharmaceutical
Eisai
Janssen Pharmaceutical K.K.
Ono Pharmaceutical
Sanofi UCB Japan
Teijin Healthcare Limited
- License Information
-
More Information
Article History
Received: 9 January 2021
Accepted: 10 April 2021
First Online: 26 April 2021
Declaration
:
: YM received a research grant and/or speaker fee from Eli Lilly Japan K.K., Chugai Pharmaceutical Co. Ltd., Pfizer Inc., Bristol Myers Squibb, and Mitsubishi Tanabe Pharma Corporation. TH received a speaker fee from GlaxoSmithKline, Chugai, Eisai, Eli Lilly and NIPPON SHINYAKU. KE is affiliated with the department, which is supported by Taisho. KE has received research grants from Abbie, Asahi-Kasei, Astellas, Chugai, Eisai, Ono Pharmaceutical, and UCB Japan. K.E. has received payments for lectures from Abbie, Asahi-Kasei, Astellas, AYUMI, Bristol-Myers Squibb, Chugai, Eisai, Eli Lilly, Janssen, Mitsubishi Tanabe, Ono Pharmaceutical, Sanofi and UCB Japan. MH belong to the department that is financially supported by Nagahama City, Shiga, Japan, Toyooka City, Hyogo, Japan and five pharmaceutical companies (Mitsubishi-Tanabe, Chugai, UCB Japan, AYUMI and Asahi-Kasei). MH has received a research and/or speaker fee from Bristol-Meyers, Eisai, Ely Lilly, and Tanabe-Mitsubishi. JS reports personal fees from Mitsubishi Tanabe Pharma Corporation, personal fees from Chugai Pharmaceutical Co. Ltd, personal fees from Asahi-Kasei Corporation, personal fees from Eli Lilly and Company, personal fees from AbbVie GK. KM received a research grant from Eisai. AO received a speaker fee from Chugai, Ono Pharmaceutical, Eli Lilly, Mitsubishi Tanabe, Asahi-Kasei and Takeda. AK received a research grant and/or speaker fee from Mitsubishi-Tanabe, Chugai, Eisai, Asahi-Kasei, Astellas, Abbie, Bristol-Myers Squibb, Ono Pharmaceutical and Pfizer.
